Journal article
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer
W Jeong, SB Kim, BH Sohn, YY Park, ES Park, SC Kim, SS Kim, RL Johnson, M Birrer, DSL Bowtell, GB Mills, A Sood, JS Lee
Anticancer Research | INT INST ANTICANCER RESEARCH | Published : 2014
Abstract
Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in o..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The study was funded by a grant from The University of Texas MD Anderson Cancer Center, Sheikh Khalifa Bin Zayed Institute for Personalized Cancer Therapy, Ovarian SPORE (NCIP50CA083639), Bio & Medical Technology Development Program Grant, Korea (M10642040002-07N4204-00210), and Scientific Research Center Program Grant, Korea (2012R1A5A1048236).